The prices of Cetirizine Dihydrochloride in the United States witnessed a continued decline during May xxxx, following a downward trend that began in the previous month. This declined mainly because of the combination of domestic policy shifts, enhancement of global supply chains, and a significant drop in the price of raw materials used in the production of pharmaceuticals.
One of the key drivers of the recent price action of Cetirizine Dihydrochloride is the newly signed executive order of the U.S. President Donald Trump. The order requires drug makers to reduce drug prices shipped out in the U.S. to the lowest levels obtained elsewhere in developed economies. The order has a xx-day grace period, after which the U.S. Department of Health and Human Services will adopt a system of reference pricing, with domestic prices compared to prices overseas in other high-income countries. This action has placed immediate pressure...
